Replies to post #136891 on Biotech Values

[mcbio]

CLDX -
Quote:
--------------------------------------------------------------------------------
If I remember from looking earlier in the day, the median number of preceding treatments for the Eribulan P3 was 4. For the CDX-011 BC trial it is a remarkable 7. I'd expect that to have a meaningful effect on background rate of ORR.
--------------------------------------------------------------------------------



A calibration of the difference between the ORR for a drug in refractory and first line:

Tarceva

a) in refractory NSCLC - 13.5% (7/52)
b) in first line NSCLC - 22.7% (12/53)

theoncologist.alphamedpress.org/content/12/7/840.full


Looking for monotherapy differences in ORR between 3rd line and 1st line and hard to find. FWIW.

Are you posting this as a general caveat on the upcoming Phase 2b data for 011? Or are you posting this to show how difficult this patient population is to treat and how meaningful any kind of response from 011 could be? And I'd be curious to know if the Phase 2a trial had patients that had a median number of 7 preceding treatments as well (wherein CLDX saw what I think could be deemed promising results).